Pricing pressures that have affected the US generics market over the last few years have stabilized and this will continue to be the case in the future, according to Teva chief Kåre Schultz. Speaking at the 2019 J.P. Morgan Healthcare Conference, he also revealed that the firm was on track with its restructuring and debt-reduction plan.
Following several years of pricing pressures, the US generics market has stabilized and will continue to do so, according to Teva president and chief executive officer Kåre Schultz.
Speaking at the 2019 J.P. Morgan Healthcare Conference in San Francisco, US, this week, he noted that there had been...